| Name | Title | Contact Details |
|---|---|---|
Andrew Schafer |
Chief Technology Officer | Profile |
Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
BioAmber is a renewable chemistry company. We use agricultural crops and transform them into green chemicals that directly substitute chemicals derived from oil. BioAmber combines industrial biotechnology and chemical catalysis into a process that offers a better carbon footprint than petrochemicals. In addition to moving away from petroleum, our process consumes CO2, directly reducing greenhouse gas emissions and aiding in the fight against global warming. Bioamber is today the only producer of bio-succinic acid, a chemical building block used in a number of applications, such as plastics, polyurethane, solvents, personal care, plasticisers, etc.
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare`s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.